Safeguarding Australia's healthcare sector with a new nuclear medicine facility
ANSTO today welcomed a significant Federal Government funding allocation to further safeguard the production of life-saving nuclear medicines in Australia.
Showing 1 - 9 of 9 results
ANSTO today welcomed a significant Federal Government funding allocation to further safeguard the production of life-saving nuclear medicines in Australia.
The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.
The Government is safeguarding Australia’s sovereign capability to produce vital nuclear medicines by launching a $30 million project to design a new world-leading manufacturing facility to be built at Lucas Heights in Sydney.
ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.
The NSW Government will invest $12.5 million to support the expansion of the Innovation Precinct at the Lucas Heights campus of the Australian Nuclear Science and Technology Organisation (ANSTO).
See details of previously published customer updates from our Health products team.
In January 2026, Mr Michael Quigley AM, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry and Innovation, and Minister for Science.